

Ref: 76/SE/LC/2025-26

Date: February 07, 2026

Scrip Code BSE: 544122
NSE: ENTERO
ISIN: INE010601016

To,
**Head, Listing Compliance Department
BSE Limited**
Phiroze Jeejeebhoy Towers Dalal Street,
Mumbai - 400 001.

**Head, Listing Compliance Department
National Stock Exchange of India Limited**
Exchange Plaza, Plot No. C/1. G Block,
Bandra -Kurla Complex, Bandra (East),
Mumbai- 400051

Dear Sir/Madam,

Subject: Update under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

This is with reference to our prior intimation vide reference no. 59/SE/LC/2025-26 dated November 12, 2025, we would like to inform you that the Company has completed acquisition of majority equity stake (51.51%) in Anand Chemiceutics Private Limited.

The details for the above acquisition (as required to be furnished pursuant to Regulation 30 and SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024) were already disclosed in our abovementioned intimation letter dated November 12, 2025.

This is for your information and records.

Yours Faithfully
For **Entero Healthcare Solutions Limited**

Sanu Kapoor
**Vice President- General Counsel, Company Secretary
& Compliance Officer**